Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs

被引：24

作者：

Hermann, Matthias ^{[1
]}

Ruschitzka, Frank ^{[1
]}

机构：

[1] Univ Zurich Hosp, Cardiovas Ctr, CH-8091 Zurich, Switzerland

来源：

ANNALS OF MEDICINE | 2007年 / 39卷 / 01期

关键词：

cardiovascular risk; coxibs; hypertension; NSAIDs;

D O I：

10.1080/07853890601073445

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way.

引用

页码：18 / 27

页数：10

共 48 条

[11] *FDA DEP HLTH HUM, 2005, BRIEF PACK NDA 21 38
[12] Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro
Fife, RS
Stott, B
Carr, RE
[J]. CANCER BIOLOGY & THERAPY, 2004, 3 (02) : 228 - 232
[13] Non-narcotic analgesic dose and risk of incident hypertension in US women
Forman, JP
Stampfer, MJ
Curhan, GC
[J]. HYPERTENSION, 2005, 46 (03) : 500 - 507
[14] Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study
Graham, DJ
Campen, D
Hui, R
Spence, M
Cheetham, C
Levy, G
Shoor, S
Graham, D
[J]. LANCET, 2005, 365 (9458) : 475 - 481
[15] Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors
Hawkey, C
Talley, NJ
Yeomans, ND
Jones, R
Sung, JJY
Långström, G
Næsdal, J
Scheiman, JM
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (05) : 1028 - 1036
[16] Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension
Hermann, M
Camici, G
Fratton, A
Hurlimann, D
Tanner, FC
Hellermann, JP
Fiedler, M
Thiery, J
Neidhart, M
Gay, RE
Gay, S
Lüscher, TF
Ruschitzka, F
[J]. CIRCULATION, 2003, 108 (19) : 2308 - 2311
[17] Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Hippisley-Cox, J
Coupland, C
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504): : 1366 - 1369
[18] Hirschowitz B I, 1994, Gastroenterologist, V2, P207
[19] Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study
Hudson, M
Richard, H
Pilote, L
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504): : 1370 - 1373
[20] Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs -: A population-based case-control study
Johnsen, SP
Larsson, H
Tarone, RE
McLaughlin, JK
Norgård, B
Friis, S
Sorensen, HT
[J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (09) : 978 - 984

← 1 2 3 4 5 →